Highlights Nicox SA

Equities

ALCOX

FR0013018124

Market Closed - Euronext Paris Other stock markets 11:35:29 2024-05-03 am EDT			5-day change	1st Jan Change
0.38 ^EUR	-1.81%		+1.60%	-14.03%

Apr. 22	Nicox: cash position of 9.1 million euros at the end of March	CF
Feb. 28	Nicox, BlackRock Sign Deal for Debt Restructuring	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nicox: cash position of 9.1 million euros at the end of March	Apr. 22	CF
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	Feb. 08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	Jan. 31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	Jan. 31	CI
Nicox: sales up 29% in 2023	Jan. 25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	Dec. 14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20	CI
Nicox Set for Euronext Growth Paris Transfer	23-04-26	MT
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	23-04-14	CI
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nicox Plans to Move Listing to Euronext Growth Paris	23-01-09	MT
Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma	22-11-07	CI
Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470	22-10-31	CI
Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial	22-09-19	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-16	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-16	CI
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology	22-07-07	CI
Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022	22-06-03	CI
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma	22-04-11	CI
Ocumension Therapeutics Says Phase III Study of Eye Drops in China Yields Positive Results	22-03-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nicox SA

Equities

ALCOX

FR0013018124

Highlights

Filters